FerroptoCure Inc Concludes Series A Round

Tokyo biotech startup FerroptoCure has raised ¥460 million in Series A funding. This money will help speed up developing therapies that use ferroptosis. Ferroptosis is a type of cell death caused by oxidative stress.

Investors are:

• ANRI
• Tokyo University of Science Innovation Capital
• Diamond Medino Capital
• Vision Incubate
• 科学技術振興事業団

Total funding from this round is expected to hit ¥960 million, thanks to extra subsidies from AMED’s Drug Discovery Venture Ecosystem Strengthening Project.

こちらもお読みください： FUJIFILM and argenx Extend Collaboration to U.S. Operations

The company will use the funds for key purposes:

• Advancing overseas clinical trials for its lead candidate, FC-004.
• Developing other pipelines.
• Expanding its capabilities for future growth.

AMED’s support shows Japan’s effort to boost its drug discovery ecosystem. They are backing ventures that focus on new therapies.

FerroptoCure focuses on ferroptosis. This research focuses on oxidative stress. It aims to treat diseases that don’t respond to usual methods. With this funding, the startup aims for global growth. It will also lead to new innovations in precision medicine and therapy discovery.